Equibles does not estimate personal net worth.
Get an email with a short summary when BridgeBio Pharma, Inc. publishes a filing, an earnings call transcript or a press release.
Get BBIO alertsAnant Sridhar is recorded as COO at BridgeBio Pharma, Inc. (BBIO). Anant Sridhar has spoken on 4 earnings calls and 1 other investor event across 1 company, most recently for BridgeBio Pharma, Inc. on October 29, 2026. BridgeBio Pharma, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at BridgeBio Pharma, Inc. includes Neil Kumar (CEO and Board Member), Charles Homcy (Chairman and Board Member), Brian Stephenson (CFO) and 7 others.
“Yes, it's a great question, and it's exciting to advance incalorate into this registrational study to reclaim HP study of incalorate and chronic hypoparathyroidism, especially at a point where it is under registrational review, enables us to further interrogate its clinical profile and advance its potential clinical…”
“And then just to add on that, implicit in some of Tom's comments is if that is where the field trends with the data, it's important to recall that the way the paradigm and the treatment regimen is studied in that approach is stabilizer first, then knockdown added on.”
“Both families are on treatment today, but more importantly, those that stay on the sidelines, which, as a reminder, makes up about 70 to 80 percent of the U.S. market.”
“For this program and ADH1 in particular, we see any successful study as a win, really a home run for this community.”
“So, as you mentioned, we reported data from the first nine participants of post-surgical hypoparathyroidism that were treated with incalerate.”
Biotechnology · Healthcare
COO
